Articles from SPR

- 12-Month Outcomes from the RESET™ Trial for Low Back Pain Recognized as Top Abstract Award winner -

CLEVELAND, July 07, 2026 (GLOBE NEWSWIRE) -- SPR announced the publication of long-term data in the journal Pain and Therapy from a cross-sectional follow-up survey of real-world patients (n=602) with chronic low back pain who had previously responded to treatment with the SPRINT Peripheral Nerve Stimulation (PNS) System. Overall, 79 percent of survey participants avoided subsequent interventions including radiofrequency ablation (RFA), permanent neurostimulator implant, and low back surgery through the period of follow-up which ranged from six months to over five years.

CLEVELAND, Ohio, June 29, 2026 (GLOBE NEWSWIRE) -- SPR has been recognized as a Top Workplace by Northeast Ohio Top Workplaces for the fifth consecutive year, marking a significant milestone that reflects the impact of a quality culture within a high-growth company. Since receiving its first Top Workplace award, SPR has more than doubled its number of employees, seen exponential revenue growth from the SPR® SPRINT® PNS System, and surpassed 50,000 patients treated– reflecting the rapid adoption of 60-day PNS and its growing impact for patients living with pain.

CLEVELAND, June 10, 2026 (GLOBE NEWSWIRE) -- SPR® announced the publication of “Observations from the RESET Clinical Trial: A Post-Hoc Per Protocol Analysis of Clinical Outcomes with Percutaneous 60-Day Medial Branch PNS in Chronic Low Back Pain” in the journal Interventional Pain Medicine. This publication is a per protocol analysis of the RESET™ clinical trial of over 200 participants, which compares the 60-day SPRINT® Peripheral Nerve Stimulation (PNS) System to a control group receiving standard interventions for the treatment of chronic low back pain, such as physical therapy, injections, or radiofrequency ablation.*